Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001025480 | SCV001187677 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-06-09 | criteria provided, single submitter | clinical testing | The c.663-5C>A intronic variant results from a C to A substitution 5 nucleotides upstream from coding exon 6 in the ATM gene. This nucleotide position is poorly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested, however, this transcript is also seen in non-carrier controls; the clinical impact of this abnormal splicing is unknown at this time (Ambry internal data). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Invitae | RCV001401699 | SCV001603529 | likely benign | Ataxia-telangiectasia syndrome | 2019-10-28 | criteria provided, single submitter | clinical testing |